Microneedles: A Promising Future for Efficient Drug Delivery in Diabetes Management

Abstract: This review's objective is to draw attention to the use of microneedles (MNs) as a state-of-the-art, novel drug delivery method for the effective management of diabetic patients. Oral, subcutaneous, nasal, and other administration methods have numerous drawbacks, including discomfort and numerous other adverse effects. As a result, this drug delivery study has shown great promise in integrating therapeutic and diagnostic components to improve diabetes treatment. The majority of glucose-sensing methods and traditional insulin treatments work by transferring physical substances through the skin. A non-invasive or minimally invasive approach can be used to administer medication using an MN-based system, which can be advantageous for painless administration, easy handling, discrete, continuous, and regulated release. In order to create a "smart" system that is specifically designed for autonomous diabetic treatment, the study discusses the latest developments in bioengineered systems such as MNs. Microneedle (MN) technology represents a transformative approach in diabetes management, offering a minimally invasive, pain-free alternative to traditional insulin delivery methods. These micro-scale needles facilitate transdermal insulin administration, bypassing gastrointestinal degradation and enhancing bioavailability. Advancements in MN design, including glucose-responsive systems and integration with nanomaterials, enable real-time glucose monitoring and controlled insulin release, mimicking pancreatic function. Such innovations not only improve glycemic control but also enhance patient compliance by reducing discomfort and simplifying administration. Moreover, MNs' potential in combining therapeutic and diagnostic functions positions them as a promising tool in personalized diabetes care. Continued research and development are essential to overcome existing challenges and fully realize MNs' capabilities in clinical settings.